Amy Domeyer-Klenske, MD, ACOG Committee on Scientific ProgramMy name is Dr. Amy Domeyer-Klenske. I am a board-certified OB GYN and a member of the ACOG Scientific Program Committee.I think right now in the world of OB-GYN, there's just so much coming at us in terms of health and health care. The needs of our patients are changing; the federal landscape is changing. There's just lots of things that are impacting the care we provide to our patients. And so, this year's theme of the meeting is called Powered by Purpose. And I really think it was a great opportunity for us to come together as a professional group and really refocus on what that purpose is for us, which is taking care of our patients. Making sure we're taking care of ourselves. And hopefully improving the health and well-being of our communities.So, one conversation or meeting that we had was really about transforming prenatal care, the model, the sort of cadence of visits and coming into your doctor's office and measuring the belly or the fundal height and listening to heart rate. A lot of that hasn't necessarily been changed in decades.And so, there's been a lot of work and a new consensus opinion from ACOG based on this research that really tells us that we can change. We really need to modernize and change how we provide prenatal care.Really thinking about personalizing prenatal care to patients, considering an individual's social needs as well as their medical needs, for example. Thinking about utilizing virtual care options when that's possible to help save people time and energy coming into the clinic if that's challenging for them, and particularly folks who may have difficulties. We think about rural care, for example, they may have difficulty coming to appointments.But really taking into account the patient's preferences and their needs when personalizing that visit cadence. And then using templates from the research that was done to help find that ideal cadence of prenatal visits.Other presentations also just focused on how we need to take care of ourselves and ensure that, you now, when we think about physician burnout and obstetrics and gynecology certainly is one of the specialties that is very much affected by that.For us to be able to take care of our patients, we certainly have to be able to be take care of ourselves.Comparing the Effects of Glucagon-Like Peptide-1 Receptor Agonists on Cardiovascular Events to Metformin in Patients With Polycystic Ovary Syndrome: A Real-World Multicenter Cohort Study Across the United StatesTina Yi Jin Hsieh, MD, Department of Obstetrics & Gynecology, Beth Israel Deaconess Medical CenterMy name is Tina Shieh. So, I'm an MD from Taiwan and currently doing research at the OB-GYN department at Beth Israel Deaconess Medical Center.So, this study utilized the TriNetX U.S. collaborative network, which includes about 60 health care organizations across the U.S. We are comparing PCOS women who use GLP-1 RA medications compared to those who use metformin medications after their diagnosis of PCOS. And then we balance the two cohorts to adjust for compounding factors using propensity score modeling.We adjusted for demographics, BMI, healthcare utilization, and some other biomarkers, including LDL, HDL, triglyceride, and HbA1c, which is the blood sugar metric.And then we followed them up to look for cardiovascular events, including arrhythmia, thrombotic disorders, cerebral vascular disease, inflammatory heart disease, ischemic heart disease and then major adverse cardiovascular events.We found that for PCOS women who use GLP-1 RAs compared to those who use metformin, there was a protective effect with those who used GLP-1RA against arrhythmia and thrombotic disorders. So, for these two outcomes, they were significant.But for cerebral vascular disease, inflammatory heart disease and ischemia heart disease and MACE there was a protective trend, but they were not significant.We think maybe it's because the median age was around 36.3. So, it's a relatively young cohort to be having cerebral vascular events and other cardiovascular events. And we restricted the cohort to those that used these two medications between 2005 to 2021 and then we ended our follow-up time in 2024. So, the minimum follow-up time for some of these patients are only three years..Sign up for our weekly HealthDay newsletter